ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Solid Tumors

This study (called ARTEMIS-003) tests a new drug called HS-20093 in patients with advanced solid tumors — with a special focus on men with metastatic prostate cancer that is no longer responding to hormone treatment (called castration-resistant prostate cancer). **You may be eligible if...** - You are 18 years or older - You have been diagnosed with locally advanced or metastatic solid tumor cancer confirmed by biopsy - Standard treatments are no longer working, are unavailable, or you cannot tolerate them - You have at least one measurable tumor on imaging - Your overall health is good (ECOG performance status 0 or 1) and life expectancy is at least 12 weeks - You are willing to provide a tumor tissue sample **You may NOT be eligible if...** - Your cancer is responding to a current treatment - You have no measurable disease on imaging - You have significant organ dysfunction (heart, liver, kidneys) - You are pregnant Talk to your doctor to see if this trial is right for you.